Multimodality imaging of somatostatin receptor-positive tumors with nuclear and bioluminescence imaging

Molecular Imaging

Volumn 11, Issue 1, 2012, Pages 27-32

  Pool, Stefan E ^a   Ten Hagen, Timo L M ^a   Koelewijn, Stuart ^a   De Jong, Marion ^a   Koning, Gerben A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; BIODISTRIBUTIONS; BIOLUMINESCENCE IMAGING; CELL LINES; EX-VIVO; GREEN FLUORESCENT PROTEIN; GROWTH PROPERTIES; IN-CONTROL; LIVER METASTASIS; MULTI-MODAL; MULTIMODALITY IMAGING; NEUROENDOCRINE TUMORS; NUDE MICE; PEPTIDE RECEPTOR; RADIONUCLIDE THERAPY; RAT LIVERS; SOMATOSTATIN RECEPTORS; SPECT/CT; TRANSFECTED CELLS; TUMOR CELL LINES; TUMOR CELLS; TUMOR MODELS; TUMOR MONITORING;

BIOLUMINESCENCE; CELL CULTURE; CELLS; MOLECULAR BIOLOGY; PHOSPHORESCENCE; RADIOGRAPHY; RATS;

TUMORS;

SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2;

ANIMAL; ARTICLE; AUTORADIOGRAPHY; FLUORESCENCE MICROSCOPY; METABOLISM; MOUSE; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; RADIOGRAPHY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL LINE;

ANIMALS; AUTORADIOGRAPHY; CELL LINE, TUMOR; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; PANCREATIC NEOPLASMS; RATS; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84857315535     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00024     Document Type: Article

References (9)

1. Pool SE, Krenning EP, Koning GA, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med 2010;40:209-18, doi:10.1053/j.semnuclmed.2009.12.001.
2. Breeman WA, Mearadji A, Capello A, et al. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3] octreotate in a rat liver micrometastases model. Int J Cancer 2003; 104:376-9, doi:10.1002/ijc.10952. (Pubitemid 36249821)
3. van Essen M, Krenning EP, Kam BL, et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009;5:382-93, doi:10.1038/nrendo.2009.105.
4. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30, doi:10.1200/JCO.2007.15. 2553.
5. McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90YDOTA-lanreotide as effective palliative therapy. Radiology 2005;237: 718-26, doi:10.1148/radiol. 2372041203. (Pubitemid 41507917)
6. Limouris GS, Chatziioannou A, Kontogeorgakos D, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 2008;35:1827-37, doi:10.1007/s00259-008- 0779-0.
7. van Essen M, Krenning EP, Kam BL, et al. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:743-8, doi:10.1007/s00259-007-0688-7.
8. Bernard BF, Krenning E, Breeman WA, et al. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 2000;21:1079-85, doi:10.1097/00006231-200011000-00015.
9. De Jong M, Bernard BF, De Bruin E, et al. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0, Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 1998;19:283-8, doi:10.1097/00006231-199803000-00013. (Pubitemid 28198201)